HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.

298 Clinical Trials
Phase 1 Clinical Trials Phase I Active
nct/study# NA / MAGE-A4

An Open-Label, Multicenter, Dose-Escalation, Phase I Study To Evaluate Safety, Pharmacokinetics, And Preliminary Anti-Tumor Activity Of Ro7444973 In Participants With Advanced And/Or Metastatic Mage A4-Positive, Solid Tumors.

Learn More
Phase 1 Clinical Trials Phase I Active
nct/study# NCT03522142 / INCB81776-101

A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Learn More
Skin and Soft Tissue Phase II Accepting Patients
nct/study# NCT04339738 / A091902

A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA

Learn More
Skin and Soft Tissue Phase III Accepting Patients
nct/study# NCT03712605 / EA6174

STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

Learn More
Skin and Soft Tissue Phase II Accepting Patients
nct/study# NCT04091750 / IST83

Phase II Study of Nivolumab/Ipilimumab plus Cabozantinib in Patients with Unresectable Advanced Melanoma

Learn More
Skin and Soft Tissue Phase II Accepting Patients
nct/study# NCT04577807 / LUMINOS-102

PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Learn More

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.